Related Experiment Video
Updated: Sep 8, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
Similar Efficacy, Safety, and Immune Improvement Through 96 Weeks in Individuals With Limited HIV-1 Treatment Options
Antonella Castagna1,2, Iacopo Marcon3, Fangfang Du4
1Infectious Diseases Unit, Vita-Salute San Raffaele University, Milan, Italy.
Abstract:
Constructing suppressive regimens for individuals with multidrug-resistant HIV-1 can be challenging. Separate analyses of 96-week outcomes from the phase 3 VIKING-3 and BRIGHTE studies demonstrate that twice-daily dolutegravir-based and fostemsavir-based regimens each provide robust viral suppression, favorable safety profiles, and CD4+ T-cell count improvement in this population. Clinical trial registration VIKING-3: ClinicalTrials.gov identification number, NCT01328041; URL, https://clinicaltrials.gov/study/NCT01328041; BRIGHTE: ClinicalTrials.gov identification number, NCT02362503; URL, https://clinicaltrials.gov/study/NCT02362503.
Related Concept Videos
Retrovirus Life Cycles
Antiviral Nucleoside Inhibitors
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Bioavailability Study Design: Single Versus Multiple Dose Studies
Inhibitors of Viral Protein Synthesis
Antimicrobial Effectiveness

